Wolters Kluwer The clinical and laboratory response to HU was dramatic in severely affected sickle cell anemia (SCA) patients. Hydroxyurea is a potent inducer of fetal hemoglobin, and evidence over the past 25 years has documented its laboratory and clinical efficacy for both adults and children with SCA. PURPOSE OF REVIEW: Sickle cell anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and early mortality. Mechanisms of action involved in the beneficial effects of hydroxyurea for sickle cell… Fig 2. 2013 Mar;336(3):177-82. doi: 10.1016/j.crvi.2012.09.006. The response to HU in children and teenagers with severe sickle cell anemia is similar to the response in adults, and no severe adverse effects were observed.We use cookies to improve your website experience. Severe neutropenia was observed in one case. N Engl J Med. COVID-19 is an emerging, rapidly evolving situation. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. eCollection 2020.Mediterr J Hematol Infect Dis. Pediatric Hematology and Oncology: Vol. Name must be less than 100 characters To learn about our use of cookies and how you can manage your cookie settings, please see our Register to receive personalised research and resources by emailEFFECT OF HYDROXYUREA IN SICKLE CELL ANEMIA: A Clinical Trial in Children and Teenagers with Severe Sickle Cell Anemia and Sickle Cell beta-Thalassemia Department of Pediatrics, Ziv Hospital, Safed, Israel Hematology Laboratory, Haemek Central Hospital, Afula, Israel Pediatric Hematology Unit and Pediatric Department B, Haemek Central Hospital, Afula, Israel Department of Pediatrics, Ziv Hospital, Safed, Israel; and the Baruch Rappaport School of Medicine, Technion, Israel Institute of Technology, Haifa, Israel Pediatric Hematology Institute, Bnai Zion Hospital, Haifa, Israel Department of Pediatrics, Ziv Hospital, Safed, Israel Department of Pediatrics, Ziv Hospital, Safed, Israel For patients who have sickle cell disease, an oral medicine called hydroxyurea may be able to help. Nineteen children and young adults with severe sickle cell disease were enrolled to the hydroxyurea treatment trial. 2010 Jul 1;115(26):5300-11. doi: 10.1182/blood-2009-04-146852. Please enable it to take advantage of the complete set of features! This study evaluated the efficacy of hydroxyurea treatment in the prevention of vaso-occlusive crises among children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. It is a powerful medicine. Mortality and morbidity rates in sickle cell disease (SCD) have been considerably reduced since the introduction of hydroxyurea (HU) in the 1990s. Fig 1. McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya AS, Thompson BW, Ware RE; BABY HUG Investigators.Pediatr Blood Cancer. doi: 10.4084/MJHID.2020.010. Epub 2015 Sep 14.F1000Res. (1999). Epub 2010 Mar 11.Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.JAMA. eCollection 2019.Oman Med J. doi: 10.12688/f1000research.22433.1. Sickle Cell Disease Hydroxyurea: What You Need to Know If you have sickle cell disease, your body makes sickle-shaped, or crescent-shaped, red blood cells. Epub 2012 Nov 9.Expert Opin Drug Saf. EFFECT OF HYDROXYUREA IN SICKLE CELL ANEMIA: A Clinical Trial in Children and Teenagers with Severe Sickle Cell Anemia and Sickle Cell beta-Thalassemia. Epub 2011 Oct 19.Blood. The patients received a mean dose of 21.3 mg/kg/day daily and were treated during a mean period of 40.3 14 months (range 20 to 68 months). 2019 Sep 11;8:21. doi: 10.1186/s40164-019-0145-x. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. No differences were observed in the R DW, reticulocyte count, Hgb S, and Hgb A2 . 2019 Oct 15;19(1):354. doi: 10.1186/s12887-019-1746-6.Mousavi Z, Yazdani Z, Moradabadi A, Hoseinpourkasgari F, Hassanshahi G.Exp Hematol Oncol. A decrease in the frequency of vaso-occlusive crises, acute chest syndrome, hemolytic crises, blood transfusions, and days spent in the hospital was demonstrated during the HU treatment period compared to the same period before.